A potential cancer drug developed from an Australian rainforest plant is set to progress to human trials, reports the Strait Times.
Quoting the AFP wires, the newspaper explains that the drug is being put forward to the next stage after fighting off inoperable tumours in pets.
Queensland firm QBiotics Limited said its EBC-46, derived from the seeds of a tropical rainforest shrub, was ready to be tested on humans after successfully treating solid tumours in more than 100 dogs, cats and horses.
“We’ve treated over 150 animals… with a variety of tumours, and we’re prepared to move into human studies,” explained chief executive Victoria Gordon.
Dr Gordon said the results so far indicated the drug could work to counter a range of malignant growths, such as skin cancers, head and neck cancer, breast cancer and prostate cancer.
She said the drug works like a detonator inside tumours, prompting inactive beneficial white cells to begin to fight and destroy the cancer.
The company is reported as spending six years developing the drug since the previously unknown molecule in the native Australian plant blushwood was discovered.
It hopes to raise enough funds to begin human trials in 2011.
Dr Gordon said the compound proves the value of retaining Australia’s unique tropical rainforests.
Source: The Strait Times (Singapore)/AFP
Filed under: rainforest, research | Tagged: afp, australia, blushwood, cancer, conservation, human trials, medical science, medicine, oncology, plants, qbiotics, queensland, rainforest, research, science, shrub, singapore, strait times, trees | Leave a comment »